Escient Pharmaceuticals Stock

escientpharma.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $243.51MM

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Escient Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Escient Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Escient Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Joshua Grass
Chief Executive Officer
Christian Weyer, MD, MAS
President and Chief Medical Officer
Marcus F. Boehm, PHD
Chief Scientific Officer
Aaron Mishel
Chief Financial Officer

Board Members

Kathleen Sereda Glaub
Chair
Ben Auspitz
Independent Director
Jason P Hafler, PHD
Independent Director
Matt Mcaviney
Independent Director
Jason Punwani
Abingworth
Kevin Raidy
Cowen Healthcare Investments
Andy Schwab
5AM Ventures
Peter Svennilson
The Column Group

News Highlights

San Diego biotech Escient Pharmaceuticals pulls in $120M to pursue novel drug candidates
Startup biotech manages to raise venture capital despite a slowdown in funding amid economic uncertainty
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.